Daily Ards Research Analysis
Today's most impactful work includes a mechanistic tour-de-force on Nipah virus polymerase with new high-throughput assays for antiviral discovery, a cross-sectional study linking persistent endothelial dysfunction to lung diffusing capacity two years after COVID-19, and an expert narrative update on pediatric VV-ECMO best practices and evidence gaps. Together, these studies advance pathogen-targeted therapeutics, clarify long COVID vascular sequelae, and refine supportive care strategies.
Summary
Today's most impactful work includes a mechanistic tour-de-force on Nipah virus polymerase with new high-throughput assays for antiviral discovery, a cross-sectional study linking persistent endothelial dysfunction to lung diffusing capacity two years after COVID-19, and an expert narrative update on pediatric VV-ECMO best practices and evidence gaps. Together, these studies advance pathogen-targeted therapeutics, clarify long COVID vascular sequelae, and refine supportive care strategies.
Research Themes
- Structure-guided antiviral discovery for henipaviruses
- Endothelial dysfunction and lung diffusing capacity in long COVID
- Pediatric VV-ECMO best practices and emerging technologies
Selected Articles
1. Cryo-EM structures of Nipah virus polymerases and high-throughput RdRp assay development enable anti-NiV drug discovery.
This mechanistic study defines structural features of the NiV L-P polymerase complex across strains and uncovers a back-priming activity. Complementary high-sensitive and high-throughput polymerase assays were established to accelerate screening of direct-acting antivirals against henipaviruses.
Impact: It combines structural virology with assay innovation, providing actionable tools and mechanistic insights that can directly inform antiviral discovery for high-consequence pathogens.
Clinical Implications: While preclinical, these assays and structural insights enable rational screening and optimization of polymerase inhibitors, potentially expediting candidate selection for future in vivo and clinical studies.
Key Findings
- Resolved multiple cryo-EM structures of full-length and truncated NiV polymerases from Malaysia and Bangladesh strains.
- Identified two conserved loops within the L protein PRNTase domain and interactions between RdRp-PRNTase and CD domains.
- Discovered a back-priming activity of the NiV polymerase using a highly sensitive radiolabeled RNA synthesis assay.
- Developed fluorescence and luminescence-based non-radioactive polymerase assays suitable for high-throughput screening of L inhibitors.
Methodological Strengths
- Integrated structural biology across multiple strains with orthogonal biochemical validation.
- Established both high-sensitivity and high-throughput assays, enabling scalable inhibitor screening.
Limitations
- Findings are limited to in vitro structural and biochemical systems without in vivo validation.
- No efficacy data for specific antiviral compounds in cellular or animal models were reported.
Future Directions: Apply the assays to high-throughput library screening, followed by medicinal chemistry optimization and in vivo efficacy/toxicity studies against henipavirus infection.
Transcription and replication of the Nipah virus (NiV) are driven by the large protein (L) together with its essential co-factor phosphoprotein (P). L encodes all the viral enzymatic functions, including RNA-dependent RNA polymerase (RdRp) activity, while the tetrameric P is multi-modular. Here, we investigate the molecular mechanism of the NiV polymerase and build tools for anti-NiV drug discovery. We analyze and compare multiple cryo-EM structures of both full-length and truncated NiV polymerases from the Malaysia and Bangladesh strains. We identify two conserved loops in the polyribonucleotidyltransferase (PRNTase) domain of L and the binding between RdRp-PRNTase and CD domains. To further assess the mechanism of NiV polymerase activity, we establish a highly sensitive radioactive-labeled RNA synthesis assay and identify a back-priming activity in the NiV polymerase as well as a fluorescence and luminescent-based non-radioactive polymerase assay to enable high-throughput screening for L protein inhibitors. The combination of structural analysis and the development of both high-sensitive and high-throughput biochemical assays will enable the identification of new direct-acting antiviral candidates for treating highly pathogenic henipaviruses.
2. Associations between lung and endothelial function in long COVID: Two years after acute infection.
In a single-visit cross-sectional study of 32 long COVID patients approximately 32 months post-infection, endothelial function remained impaired and correlated with lung diffusing capacity (KCO). Simple regression suggested KCO explained 29% of the variance in brachial artery basal diameter.
Impact: It provides quantitative evidence linking pulmonary gas exchange capacity to persistent endothelial dysfunction long after COVID-19, informing hypotheses on vascular-lung interplay in post-viral syndromes.
Clinical Implications: Findings support cardiovascular risk assessment and endothelial-targeted rehabilitation or preventive strategies in long COVID patients with reduced gas transfer, guiding follow-up beyond the respiratory clinic.
Key Findings
- Endothelial function (FMD) remained impaired on average two years after acute COVID-19.
- Significant correlation between brachial artery basal diameter and lung function, especially KCO (p < 0.001; r = 0.560).
- KCO alone explained 29% of the variance in basal diameter in simple linear regression.
Methodological Strengths
- Use of standardized vascular (FMD) and pulmonary function testing with quantitative reporting.
- Statistical analysis included correlation and simple regression to estimate variance explained.
Limitations
- Small sample size (N=32) and cross-sectional design limit causal inference and generalizability.
- Single-center, single-visit assessment without pre-infection baselines or longitudinal follow-up.
Future Directions: Prospective longitudinal cohorts with vascular and pulmonary phenotyping should test mechanisms and evaluate targeted interventions to improve endothelial health in long COVID.
BACKGROUND: endothelial cells may be a primary source for the initiation and spread of Acute Respiratory Distress Syndrome (ARDS) caused by SARS-CoV-2, resulting in severe endothelial injury and widespread thrombosis. OBJECTIVE: The objective of this study was to evaluate the influence of lung function on the vascular response of patients with long COVID. METHODS: This is an observational and cross-sectional study. Only one visit was performed, during which the evaluation form was completed and the post-COVID-19 Functional Status Scale (PCFS) was applied. In addition, participants underwent the assessment of flow-mediated vasodilation in the brachial artery and the assessment of pulmonary function. RESULTS: A total of 32 participants were included, of which 19 (59 %) were women. The mean age was 55.8 ± 8.6 years, with a mean weight of 88.96 ± 21.66 kg. The participants had an average time of 32.25 months since the acute phase. The patients had an average of FEV₁/FVC 81.15±14.7 ( %) and KCO 93.72±7.95 ( %). FMD had an average of -0.21±11.24 ( %), indicating still impaired endothelial function. We found correlation between basal diameter (-0.21 [-4.26 to 3.84]) vs lung function variables, especially with the variable KCO ( %) (p < 0.001; r = 0.560). When we perform simple linear regression KCO ( %) indicates that this variable alone influences 29 % of the response to the basal diameter of the participants. CONCLUSION: Two years after recovery from COVID-19 infection, the patients present changes in endothelial function, which have important implications for individuals when it comes to cardiovascular health.
3. An updated guide for clinicians: extracorporeal membrane oxygenation for pediatric patients with refractory acute respiratory failure.
This expert narrative review synthesizes current practices and unanswered questions in pediatric VV-ECMO, covering indications, cannulation, ventilator/anticoagulation strategies, fluids, and weaning. It also surveys emerging technologies and calls for coordinated, high-quality research to define best practices.
Impact: It consolidates practical guidance across critical aspects of pediatric VV-ECMO and identifies priority knowledge gaps, aiding standardization and future trial design.
Clinical Implications: Clinicians can align VV-ECMO practices with contemporary expert recommendations across cannulation, ventilation, anticoagulation, and weaning while recognizing areas where evidence is insufficient and trials are needed.
Key Findings
- Summarizes core elements of pediatric VV-ECMO, including indications/contraindications, cannulation strategies, ventilator management, anticoagulation, fluid management, and weaning/decannulation.
- Highlights advances and emerging technologies influencing pediatric ECMO practice.
- Identifies substantial gaps and calls for high-quality, collaborative research to define best practices.
Methodological Strengths
- Comprehensive scope across technical and clinical management domains.
- Expert synthesis provides practical recommendations aligned with current practice trends.
Limitations
- Narrative review without systematic methods (no PRISMA), increasing risk of selection bias.
- Lack of quantitative synthesis or meta-analysis limits strength of evidence.
Future Directions: Develop multi-center prospective registries and randomized trials to test standardized VV-ECMO protocols in pediatrics, including anticoagulation and ventilator strategies.
INTRODUCTION: Extracorporeal membrane oxygenation (ECMO) remains a mainstay for refractory respiratory failure in select pediatric patients. Clinical practice surrounding its use continues to evolve, reflecting advances in technology, management strategies, and patient selection. Ongoing research and innovation are actively shaping VV-ECMO's future directions aimed at optimizing outcomes and increasing understanding of best practices. AREAS COVERED: This review summarizes the fundamental concepts of VV-ECMO and highlights established practices and ongoing questions with a focus on indications/contraindications, cannulation, ventilator management, anticoagulation, fluid management, and weaning/decannulation. We also examine recent advancements and emerging technologies that are shaping the evolution of pediatric ECMO therapy. Narrative literature review of the PubMed central database was utilized to help inform this review. EXPERT OPINION: Despite recent progress in pediatric VV-ECMO, substantial gaps remain in understanding optimal practices. And while there are many promising advances, there is a need for high-quality, collaborative research to further define best practices and guide ongoing future improvements for this life-sustaining therapy.